Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (2) · (multiple, generic dominant) (1) · Minipress (1)

Alpha-1 Adrenergic Antagonist (1) · Analgesic (2) · GABAergic (1) · Opioid (2) · Prodrug (1) · Research material (1)

Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug of GHB (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Selective alpha-1 adrenergic receptor antagonist. Lowers peripheral vascular resistance via vasodilation; in the CNS, blunts noradrenergic hyperarousal thought to drive trauma-related nightmares. (1)

None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-000005D0-QINU`"', '"`UNIQ--vote-000005D1-QINU`"', '"`UNIQ--vote-000005D2-QINU`"' (1)

None (2) · 1 mg at bedtime (PTSD nightmares); 1 mg BID–TID (HTN) (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (2) · 1, 2, 5 mg caps (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (2) · 360 mg/day (1) · 40 mg/d (1)

None (2) · Oral (1) · PO (only formulation marketed in the US). (1)

None (2) · 30–60 min (PO) (1) · 30–90 min (1)

None (2) · 4–6 hours (1) · 6–8 h (1)

None (2) · 2.5–3 hours (1) · 2–3 h (1)

None (2) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~60% (1)

None (2) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Category C (1)

None (2) · Rx-only in US (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)